nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosinopril—ACE—renal artery—nephrolithiasis	0.0731	0.41	CbGeAlD
Fosinopril—Atrial rhythm—Hydrochlorothiazide—nephrolithiasis	0.0556	0.0898	CcSEcCtD
Fosinopril—Swelling of limb—Hydrochlorothiazide—nephrolithiasis	0.0556	0.0898	CcSEcCtD
Fosinopril—Limb paresis—Hydrochlorothiazide—nephrolithiasis	0.0441	0.0713	CcSEcCtD
Fosinopril—Monoparesis—Hydrochlorothiazide—nephrolithiasis	0.0369	0.0597	CcSEcCtD
Fosinopril—Rhythm idioventricular—Hydrochlorothiazide—nephrolithiasis	0.0369	0.0597	CcSEcCtD
Fosinopril—ACE—nephron—nephrolithiasis	0.0256	0.143	CbGeAlD
Fosinopril—Skin discomfort—Hydrochlorothiazide—nephrolithiasis	0.0231	0.0373	CcSEcCtD
Fosinopril—ACE—urine—nephrolithiasis	0.0205	0.115	CbGeAlD
Fosinopril—Oral lesion—Hydrochlorothiazide—nephrolithiasis	0.0183	0.0296	CcSEcCtD
Fosinopril—Angiitis necrotising—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0235	CcSEcCtD
Fosinopril—Xanthopsia—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0235	CcSEcCtD
Fosinopril—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0135	0.0665	CbGpPWpGaD
Fosinopril—Conduction disorder—Hydrochlorothiazide—nephrolithiasis	0.0127	0.0205	CcSEcCtD
Fosinopril—Vasculitis necrotising—Hydrochlorothiazide—nephrolithiasis	0.0127	0.0205	CcSEcCtD
Fosinopril—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0125	0.0617	CbGpPWpGaD
Fosinopril—Sialoadenitis—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0176	CcSEcCtD
Fosinopril—Bad taste—Hydrochlorothiazide—nephrolithiasis	0.0105	0.017	CcSEcCtD
Fosinopril—Oral disorder—Hydrochlorothiazide—nephrolithiasis	0.0105	0.017	CcSEcCtD
Fosinopril—Abnormal faeces—Hydrochlorothiazide—nephrolithiasis	0.00931	0.015	CcSEcCtD
Fosinopril—Feeling cold—Hydrochlorothiazide—nephrolithiasis	0.00931	0.015	CcSEcCtD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.00869	0.0428	CbGpPWpGaD
Fosinopril—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.00847	0.0418	CbGpPWpGaD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.00806	0.0397	CbGpPWpGaD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00795	0.0392	CbGpPWpGaD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00795	0.0392	CbGpPWpGaD
Fosinopril—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.00786	0.0388	CbGpPWpGaD
Fosinopril—SLC15A1—nephron tubule—nephrolithiasis	0.0077	0.0432	CbGeAlD
Fosinopril—Local swelling—Hydrochlorothiazide—nephrolithiasis	0.00761	0.0123	CcSEcCtD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00737	0.0364	CbGpPWpGaD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00737	0.0364	CbGpPWpGaD
Fosinopril—SLC15A1—renal system—nephrolithiasis	0.007	0.0393	CbGeAlD
Fosinopril—Arrhythmia supraventricular—Hydrochlorothiazide—nephrolithiasis	0.00686	0.0111	CcSEcCtD
Fosinopril—SLC15A1—kidney—nephrolithiasis	0.00676	0.0379	CbGeAlD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00602	0.0297	CbGpPWpGaD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.0056	0.0276	CbGpPWpGaD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00559	0.0275	CbGpPWpGaD
Fosinopril—Trauma—Hydrochlorothiazide—nephrolithiasis	0.00559	0.00903	CcSEcCtD
Fosinopril—ACE—nephron tubule—nephrolithiasis	0.00552	0.031	CbGeAlD
Fosinopril—Epigastric pain—Hydrochlorothiazide—nephrolithiasis	0.0055	0.00889	CcSEcCtD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.0052	0.0256	CbGpPWpGaD
Fosinopril—ACE—renal system—nephrolithiasis	0.00502	0.0281	CbGeAlD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00499	0.0246	CbGpPWpGaD
Fosinopril—ACE—kidney—nephrolithiasis	0.00485	0.0272	CbGeAlD
Fosinopril—SLC15A2—nephron tubule—nephrolithiasis	0.00481	0.027	CbGeAlD
Fosinopril—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.00475	0.00767	CcSEcCtD
Fosinopril—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00475	0.00767	CcSEcCtD
Fosinopril—ACE—cortex of kidney—nephrolithiasis	0.00472	0.0265	CbGeAlD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00463	0.0228	CbGpPWpGaD
Fosinopril—SLC15A2—renal system—nephrolithiasis	0.00437	0.0245	CbGeAlD
Fosinopril—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00432	0.00699	CcSEcCtD
Fosinopril—SLC15A2—kidney—nephrolithiasis	0.00423	0.0237	CbGeAlD
Fosinopril—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.00419	0.00677	CcSEcCtD
Fosinopril—SLC15A2—cortex of kidney—nephrolithiasis	0.00412	0.0231	CbGeAlD
Fosinopril—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.00394	0.00637	CcSEcCtD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00388	0.0191	CbGpPWpGaD
Fosinopril—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.00386	0.00625	CcSEcCtD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0036	0.0178	CbGpPWpGaD
Fosinopril—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00359	0.00581	CcSEcCtD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00355	0.0175	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00355	0.0175	CbGpPWpGaD
Fosinopril—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.00347	0.00561	CcSEcCtD
Fosinopril—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00339	0.00548	CcSEcCtD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0033	0.0162	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0033	0.0162	CbGpPWpGaD
Fosinopril—Numbness—Hydrochlorothiazide—nephrolithiasis	0.00321	0.00518	CcSEcCtD
Fosinopril—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.00307	0.00496	CcSEcCtD
Fosinopril—Gout—Hydrochlorothiazide—nephrolithiasis	0.00285	0.0046	CcSEcCtD
Fosinopril—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.00273	0.0044	CcSEcCtD
Fosinopril—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00269	0.00435	CcSEcCtD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00269	0.0133	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00269	0.0133	CbGpPWpGaD
Fosinopril—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00422	CcSEcCtD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.0025	0.0123	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.0025	0.0123	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.0025	0.0123	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.0025	0.0123	CbGpPWpGaD
Fosinopril—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00404	CcSEcCtD
Fosinopril—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00389	CcSEcCtD
Fosinopril—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00389	CcSEcCtD
Fosinopril—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.00237	0.00383	CcSEcCtD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00232	0.0114	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00232	0.0114	CbGpPWpGaD
Fosinopril—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00223	0.0036	CcSEcCtD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00223	0.011	CbGpPWpGaD
Fosinopril—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00359	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00221	0.0109	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00221	0.0109	CbGpPWpGaD
Fosinopril—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00355	CcSEcCtD
Fosinopril—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00355	CcSEcCtD
Fosinopril—Swelling—Hydrochlorothiazide—nephrolithiasis	0.00219	0.00354	CcSEcCtD
Fosinopril—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00218	0.00352	CcSEcCtD
Fosinopril—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00216	0.00349	CcSEcCtD
Fosinopril—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00346	CcSEcCtD
Fosinopril—Injury—Hydrochlorothiazide—nephrolithiasis	0.0021	0.00339	CcSEcCtD
Fosinopril—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00208	0.00336	CcSEcCtD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00207	0.0102	CbGpPWpGaD
Fosinopril—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00206	0.00334	CcSEcCtD
Fosinopril—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00206	0.00332	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00205	0.0101	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00205	0.0101	CbGpPWpGaD
Fosinopril—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00331	CcSEcCtD
Fosinopril—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00331	CcSEcCtD
Fosinopril—Purpura—Hydrochlorothiazide—nephrolithiasis	0.002	0.00324	CcSEcCtD
Fosinopril—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00199	0.00321	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00197	0.00973	CbGpPWpGaD
Fosinopril—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00194	0.00313	CcSEcCtD
Fosinopril—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00192	0.0031	CcSEcCtD
Fosinopril—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0019	0.00307	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00183	0.00903	CbGpPWpGaD
Fosinopril—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00296	CcSEcCtD
Fosinopril—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00181	0.00292	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.0018	0.00889	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.0018	0.00889	CbGpPWpGaD
Fosinopril—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00286	CcSEcCtD
Fosinopril—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00176	0.00285	CcSEcCtD
Fosinopril—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00176	0.00285	CcSEcCtD
Fosinopril—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00282	CcSEcCtD
Fosinopril—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00281	CcSEcCtD
Fosinopril—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00281	CcSEcCtD
Fosinopril—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00171	0.00276	CcSEcCtD
Fosinopril—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.0017	0.00275	CcSEcCtD
Fosinopril—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00168	0.00271	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00167	0.00826	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00167	0.00826	CbGpPWpGaD
Fosinopril—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00167	0.0027	CcSEcCtD
Fosinopril—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00167	0.0027	CcSEcCtD
Fosinopril—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00164	0.00264	CcSEcCtD
Fosinopril—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00163	0.00263	CcSEcCtD
Fosinopril—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00156	0.00252	CcSEcCtD
Fosinopril—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00155	0.00251	CcSEcCtD
Fosinopril—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00154	0.00249	CcSEcCtD
Fosinopril—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00154	0.00248	CcSEcCtD
Fosinopril—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00152	0.00246	CcSEcCtD
Fosinopril—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00152	0.00245	CcSEcCtD
Fosinopril—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.0015	0.00242	CcSEcCtD
Fosinopril—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00148	0.00238	CcSEcCtD
Fosinopril—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00147	0.00237	CcSEcCtD
Fosinopril—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00146	0.00236	CcSEcCtD
Fosinopril—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00146	0.00236	CcSEcCtD
Fosinopril—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00146	0.00236	CcSEcCtD
Fosinopril—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00145	0.00234	CcSEcCtD
Fosinopril—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00227	CcSEcCtD
Fosinopril—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00226	CcSEcCtD
Fosinopril—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00139	0.00224	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00137	0.00674	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00137	0.00674	CbGpPWpGaD
Fosinopril—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00136	0.0022	CcSEcCtD
Fosinopril—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00134	0.00216	CcSEcCtD
Fosinopril—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00134	0.00216	CcSEcCtD
Fosinopril—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00133	0.00215	CcSEcCtD
Fosinopril—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00133	0.00214	CcSEcCtD
Fosinopril—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00132	0.00213	CcSEcCtD
Fosinopril—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00129	0.00208	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00127	0.00627	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00127	0.00627	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00127	0.00626	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00127	0.00626	CbGpPWpGaD
Fosinopril—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00126	0.00204	CcSEcCtD
Fosinopril—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00201	CcSEcCtD
Fosinopril—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00124	0.002	CcSEcCtD
Fosinopril—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00119	0.00193	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00118	0.00582	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00118	0.00582	CbGpPWpGaD
Fosinopril—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00115	0.00185	CcSEcCtD
Fosinopril—Tension—Hydrochlorothiazide—nephrolithiasis	0.00114	0.00184	CcSEcCtD
Fosinopril—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00114	0.00184	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00113	0.00559	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00113	0.00559	CbGpPWpGaD
Fosinopril—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00113	0.00182	CcSEcCtD
Fosinopril—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00181	CcSEcCtD
Fosinopril—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.0011	0.00177	CcSEcCtD
Fosinopril—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00109	0.00176	CcSEcCtD
Fosinopril—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00108	0.00174	CcSEcCtD
Fosinopril—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00107	0.00174	CcSEcCtD
Fosinopril—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00107	0.00173	CcSEcCtD
Fosinopril—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00106	0.00172	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00105	0.00518	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00105	0.00518	CbGpPWpGaD
Fosinopril—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00105	0.00169	CcSEcCtD
Fosinopril—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00104	0.00169	CcSEcCtD
Fosinopril—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00104	0.00168	CcSEcCtD
Fosinopril—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00104	0.00168	CcSEcCtD
Fosinopril—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00103	0.00166	CcSEcCtD
Fosinopril—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00102	0.00165	CcSEcCtD
Fosinopril—Cough—Hydrochlorothiazide—nephrolithiasis	0.00101	0.00164	CcSEcCtD
Fosinopril—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00099	0.0016	CcSEcCtD
Fosinopril—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00099	0.0016	CcSEcCtD
Fosinopril—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00099	0.0016	CcSEcCtD
Fosinopril—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.000978	0.00158	CcSEcCtD
Fosinopril—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000968	0.00156	CcSEcCtD
Fosinopril—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.000957	0.00155	CcSEcCtD
Fosinopril—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.000949	0.00153	CcSEcCtD
Fosinopril—Oedema—Hydrochlorothiazide—nephrolithiasis	0.000949	0.00153	CcSEcCtD
Fosinopril—Shock—Hydrochlorothiazide—nephrolithiasis	0.000934	0.00151	CcSEcCtD
Fosinopril—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.000929	0.0015	CcSEcCtD
Fosinopril—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000926	0.0015	CcSEcCtD
Fosinopril—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.000917	0.00148	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000906	0.00447	CbGpPWpGaD
Fosinopril—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.000905	0.00146	CcSEcCtD
Fosinopril—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.000887	0.00143	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000865	0.0014	CcSEcCtD
Fosinopril—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000858	0.00139	CcSEcCtD
Fosinopril—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000852	0.00138	CcSEcCtD
Fosinopril—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000846	0.00137	CcSEcCtD
Fosinopril—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.000844	0.00136	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000841	0.00414	CbGpPWpGaD
Fosinopril—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.000835	0.00135	CcSEcCtD
Fosinopril—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000825	0.00133	CcSEcCtD
Fosinopril—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000818	0.00132	CcSEcCtD
Fosinopril—Pain—Hydrochlorothiazide—nephrolithiasis	0.000812	0.00131	CcSEcCtD
Fosinopril—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000812	0.00131	CcSEcCtD
Fosinopril—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000782	0.00126	CcSEcCtD
Fosinopril—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000776	0.00125	CcSEcCtD
Fosinopril—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.000754	0.00122	CcSEcCtD
Fosinopril—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00075	0.00121	CcSEcCtD
Fosinopril—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00075	0.00121	CcSEcCtD
Fosinopril—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000699	0.00113	CcSEcCtD
Fosinopril—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000681	0.0011	CcSEcCtD
Fosinopril—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000671	0.00108	CcSEcCtD
Fosinopril—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000649	0.00105	CcSEcCtD
Fosinopril—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000628	0.00101	CcSEcCtD
Fosinopril—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000603	0.000975	CcSEcCtD
Fosinopril—Rash—Hydrochlorothiazide—nephrolithiasis	0.000598	0.000967	CcSEcCtD
Fosinopril—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000598	0.000966	CcSEcCtD
Fosinopril—Headache—Hydrochlorothiazide—nephrolithiasis	0.000595	0.000961	CcSEcCtD
Fosinopril—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000564	0.000911	CcSEcCtD
